A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The t(8;21)(q22;q22) translocation is one of the most common genetic abnormalities in acute myeloid leukemia (AML), identified in 15% of all cases of AML, including 40-50% of FAB M2 subtype and rare cases of M0, M1 and M4 subtypes. The most commonly known AML1-ETO fusion protein (full-length AML1-ETO) from this translocation has 752 amino acids and contains the N-terminal portion of RUNX1 (also known as AML1, CBFalpha2 or PEBP2alphaB), including its DNA binding domain, and almost the entire RUNX1T1 (also known as MTG8 or ETO) protein. Although alterations of gene expression and hematopoietic cell proliferation have been reported in the presence of AML1-ETO, its expression does not lead to the development of leukemia. Here, we report the identification of a previously unknown alternatively spliced isoform of the AML1-ETO transcript, AML1-ETO9a, that includes an extra exon, exon 9a, of the ETO gene. AML1-ETO9a encodes a C-terminally truncated AML1-ETO protein of 575 amino acids. Expression of AML1-ETO9a leads to rapid development of leukemia in a mouse retroviral transduction-transplantation model. More importantly, coexpression of AML1-ETO and AML1-ETO9a results in the substantially earlier onset of AML and blocks myeloid cell differentiation at a more immature stage. These results indicate that fusion proteins from alternatively spliced isoforms of a chromosomal translocation may work together to induce cancer development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the ETO domains that recruit corepressors are frequently deleted from the RUNX1-ETO leukemia fusion protein seen in primary AML cells.41,42”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [42]
Citations
Cites
The Transcriptional Landscape of the Mammalian Genome
Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M. C., Maeda, N., Oyama, R., Ravasi, T., Lenhard, B., Wells, C., et al. (2005) · Science · doi:10.1126/science.1112014 · Cited by 3,499 · cited 1×
“The widespread existence of alternatively spliced forms of transcripts has only recently been recognized as a result of advances in mammalian genomic analysi”
BackgroundA clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617 · cited 1×
“We performed hematopoietic progenitor population analysis in leukemic mice with multicolor staining as described previousl”
MethodIdentification of Clonogenic Common Lymphoid Progenitors in Mouse Bone Marrow
Kondo, M., Weissman, I. L., & Akashi, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80453-5 · Cited by 2,253 · cited 1×
“We performed hematopoietic progenitor population analysis in leukemic mice with multicolor staining as described previousl”
MethodPear, W. S., Miller, J. P., Xu, L., Pui, J. C., Soffer, B., Quackenbush, R. C., Pendergast, A. M., Bronson, R., Aster, J. C., Scott, M. L., et al. (1998) · Blood · doi:10.1182/blood.v92.10.3780 · Cited by 755
Miyoshi, H., Kozu, T., Shimizu, K., Enomoto, K., Maseki, N., Kaneko, Y., Kamada, N., & Ohki, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05933.x · Cited by 498
Higuchi, M., O'Brien, D., Kumaravelu, P., Lenny, N., Yeoh, E.-J., & Downing, J. R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00016-8 · Cited by 440 · cited 1×
“It is well known that the commonly studied full-length AE protein is not sufficient to induce leukemia in either human or mouse hematopoietic cell”
BackgroundYuan, Y., Zhou, L., Miyamoto, T., Iwasaki, H., Harakawa, N., Hetherington, C. J., Burel, S. A., Lagasse, E., Weissman, I. L., Akashi, K., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171321298 · Cited by 431 · cited 1×
“Full-length AML1-ETO is specifically expressed in myeloid cells under the control of the MRP8 promoter in MRP8-AE transgenic mic”
BackgroundSelf-citationBethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice
Kogan, S. C., Ward, J. M., Anver, M. R., Berman, J. J., Brayton, C., Cardiff, R. D., Carter, J. S., de Coronado, S., Downing, J. R., Fredrickson, T. N., et al. (2002) · Blood · doi:10.1182/blood.v100.1.238 · Cited by 418 · cited 1×
“According to the classification of the hematopathology subcommittee of the Mouse Model of Human Cancers Consortium (MMHCC”
MethodOkuda, T., Cai, Z., Yang, S., Lenny, N., Lyu, C.-J., van Deursen, J. M. A., Harada, H., & Downing, J. R. (1998) · Blood · doi:10.1182/blood.v91.9.3134 · Cited by 372
The t(8;21) Fusion Protein Interferes with AML-1B-Dependent Transcriptional Activation
Meyers, S., Lenny, N., & Hiebert, S. W. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.1974 · Cited by 368
Cited by
Items 101–200 of 280
CD97 is a critical regulator of acute myeloid leukemia stem cell function
Martin, G. H., Roy, N., Chakraborty, S., Desrichard, A., Chung, S. S., Woolthuis, C. M., Hu, W., Berezniuk, I., Garrett-Bakelman, F. E., Hamann, J., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190598 · Cited by 49
“Thus, we tested the leukemogenic potential of AML1-ETO9a (AE9a), a C-terminally truncated AML1-ETO protein of 575 amino acids considered to mimic human AML1-ETO (t(8;21)) AML when retrovirally expressed (Yan et al., 2006), in the CD97 deficient context.”
Gatekeeper function of the RUNX1 transcription factor in acute leukemia
Niebuhr, B., Fischer, M., Täger, M., Cammenga, J., & Stocking, C. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.07.018 · Cited by 48
Inhibitory leukocyte immunoglobulin-like receptors in cancer development
Zhang, F., Zheng, J., Kang, X., Deng, M., Lu, Z., Kim, J., & Zhang, C. C. (2015) · Science China Life Sciences · doi:10.1007/s11427-015-4925-1 · Cited by 47
Okumura, A. J., Peterson, L. F., Okumura, F., Boyapati, A., & Zhang, D. (2008) · Blood · doi:10.1182/blood-2007-11-124735 · Cited by 48
Self-citationALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia
Wang, Y., Skibbe, J. R., Hu, C., Dong, L., Ferchen, K., Su, R. J., Li, C., Huang, H., Weng, H., Huang, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01913-y · Cited by 44
Self-citationRNA sequestration in P-bodies sustains myeloid leukaemia
Kodali, S., Proietti, L., Valcárcel, G., López-Rubio, A. V., Pessina, P., Eder, T., Shi, J., Jen, A., Lupión-Garcia, N., Starner, A. C., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01489-6 · Cited by 49
“Similar results were obtained using a transplantation-based model of human AML driven by the (t8;21) chromosomal translocation, which gives rise to the RUNX1::RUNX1T1 (AML1-ETO9a) fusion gene 28 .”
Steffen, B., Knop, M., Bergholz, U., Vakhrusheva, O., Rode, M., Köhler, G., Henrichs, M. P., Bulk, E., Hehn, S., Stehling, M., et al. (2011) · Blood · doi:10.1182/blood-2009-09-242545 · Cited by 40
Draper, J. E., Sroczyńska, P., Tsoulaki, O., Leong, H. S., Fadlullah, M. Z. H., Miller, C. J., Kouskoff, V., & Lacaud, G. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005814 · Cited by 43
“The AML1-ETO9aIRES-GFP/rtTAmice were generated as follows: HA-tagged AML1-ETO9a cDNAs (provided by the Zhang laboratory [47]) were subcloned into a tet-ON vector in front of an IRES-GFP as described [69].”
BackgroundMethodPeterson, L. F., Wang, Y., Lo, M.-C., Yan, M., Kanbe, E., & Zhang, D.-E. (2007) · Leukemia · doi:10.1038/sj.leu.2404849 · Cited by 39
Self-citationGu, H., Chen, C., Hou, Z.-S., He, X., Xie, S., Ni, J., Qian, C., Cheng, X., Jiang, T., Yang, C., et al. (2024) · Blood · doi:10.1182/blood.2023022202 · Cited by 40
The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells
Staber, P. B., Zhang, P., Ye, M., Welner, R. S., Levantini, E., Di Ruscio, A., Ebralidze, A. K., Bach, C., Zhang, H., Zhang, J., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550855 · Cited by 36
“A truncated form of the AML/ETO fusion protein (AML/ETO9a) efficiently induces leukemia when expressed in an MigR1 retrovirus in fetal liver cells.(31) Here we show that transducing E14.”
BackgroundMethodBoddicker, R. L., Koltes, J. E., Fritz‐Waters, E. R., Koesterke, L., Weeks, N., Yin, T., Mani, V., Nettleton, D., Reecy, J. M., Baumgard, L. H., et al. (2016) · Animal Genetics · doi:10.1111/age.12468 · Cited by 36
We skip to work: alternative splicing in normal and malignant myelopoiesis
Wong, A. C. H., Rasko, J. E. J., & Wong, J. J. L. (2018) · Leukemia · doi:10.1038/s41375-018-0021-4 · Cited by 38
Fang, H., Zhang, B., Pan, X., Gao, L., Zhen, T., Zhao, H., Ma, L., Xie, J. Y., Liu, Z., Yu, X., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121341109 · Cited by 36
“It has been established that AE9a bears a much stronger leukemogenic activity than AE in murine system (10), and a similar situation might exist in human setting (11).”
BackgroundMethodInfluentialSelf-citationCharacterization of RUNX1T1, an Adipogenesis Regulator in Ovine Preadipocyte Differentiation
Deng, K., Ren, C., Liu, Z., Gao, X., Fan, Y., Zhang, G., Zhang, Y., El-Samahy, M. A., Wang, F., & You, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051300 · Cited by 35
“However, the RUNX1T1 coding sequence encodes 271, 579, and 662 amino acids in cattle, mice, and humans, respectively [17,18].”
BackgroundTranscriptional networks in acute myeloid leukemia
Thoms, J. A. I., Beck, D., & Pimanda, J. E. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22794 · Cited by 34
Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia
Dou, L., Yan, F., Pang, J., Zheng, D., Li, D., Gao, L., Wang, L., Xu, Y., Shi, J., Wang, Q., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12960-6 · Cited by 35
Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression
Wang, L., Man, N., Sun, X., Tan, Y., García‐Cao, M., Liu, F., Hatlen, M. A., Xu, H., Huang, G., Mattlin, M., et al. (2015) · Blood · doi:10.1182/blood-2015-03-635532 · Cited by 39
Deregulated transcription factors in leukemia
Shima, Y., & Kitabayashi, I. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0905-9 · Cited by 36
Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications
Gonzales, F., Barthélémy, A., Peyrouze, P., Fenwarth, L., Preudhomme, C., Duployez, N., & Cheok, M. H.-C. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1915991 · Cited by 43
Mtg16/Eto2 Contributes to Murine T-Cell Development
Hunt, A. A., Fischer, M. A., Engel, M. E., & Hiebert, S. W. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01458-10 · Cited by 35
“Rather than contributing to the formation of acute leukemia, deletion of these domains has been associated with increasing the activity of the t(8;21) fusion protein (46), suggesting that these domains play a negative regulatory role.”
BackgroundLo, M., Peterson, L. F., Yan, M., Cong, X., Jin, F., Shia, W.-J., Matsuura, S., Ahn, E.-Y. E., Komeno, Y., Ly, M., et al. (2012) · Blood · doi:10.1182/blood-2011-12-395335 · Cited by 39
Self-citationMolecular Mechanisms Involved in the Progression of Myelodysplastic Syndrome
Nolte, F., & Hofmann, W.-K. (2010) · Future Oncology · doi:10.2217/fon.09.175 · Cited by 34
“Another example of a gene mutation that is thought to induce leukemia by itself is a novel truncated iso form of AML1/ETO, AML1/ETO9a, which was detected in samples from t(8;21)positive AML [79].”
BackgroundOchi, K., Morita, M., Wilkinson, A. C., Iwama, A., & Yamazaki, S. (2021) · Nature Communications · doi:10.1038/s41467-021-23763-z · Cited by 27
JAK inhibitors suppress t(8;21) fusion protein-induced leukemia
Lo, M.-C., Peterson, L. F., Yan, M., Cong, X., Hickman, J. H., DeKelver, R. C., Niewerth, D., & Zhang, D.-E. (2013) · Leukemia · doi:10.1038/leu.2013.197 · Cited by 31
Self-citationA leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy
Boyapati, A., Yan, M., Peterson, L. F., Biggs, J. R., Beau, M. M. L., & Zhang, D. (2006) · Blood · doi:10.1182/blood-2006-09-045583 · Cited by 34
Self-citationGuo, C. H., Hu, Q., Yan, C., & Zhang, J. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00073-09 · Cited by 33
“ETO and its derivatives, 150 ng; Gal4-HEB(1-548) and its derivatives, 10 ng or”
BackgroundMiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO
Kohrs, N., Kolodziej, S., Kuvardina, O. N., Herglotz, J., Yillah, J., Herkt, S. C., Piechatzek, A., Salinas, G., Lingner, T., Wichmann, C. W., et al. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005946 · Cited by 35
Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles
Hatlen, M. A., Arora, K. S., Vacic, V., Grabowska, E. A., Liao, W., Riley-Gillis, B. M., Oschwald, D. M., Wang, L., Joergens, J. E., Shih, A. H., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150524 · Cited by 30
“Expression of AML1-ETO in Cdkn1a-null cells or expression of AML1ETO9a, a splice variant of AML1-ETO, in WT cells can induce fully penetrant AML after a prolonged latency (Yan et al., 2006; Peterson et al., 2007b).”
BackgroundFusion transcripts: Unexploited vulnerabilities in cancer?
Neckles, C., Rajan, S. S., & Caplen, N. J. (2019) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1562 · Cited by 30
“…gene related to the utilization of different RUNX1 promoters and alternative RUNX1T1 exons (Era et al., 1995; Erickson et al., 1992; Kozu, Fukuyama, Yamami, Akagi, & Kaneko, 2005; Kozu et al., 1993; LaFiura et al., 2008; Mannari, Gascoyne, Dunne, Chaplin, & Young, 2010; M. Yan et al., 2006).”
BackgroundShao, Y.-L., Li, Y.-Q., Li, M., Wang, L., Zhou, H.-S., Liu, D., Yu, L., Lin, J., & Gao, X. (2023) · Leukemia · doi:10.1038/s41375-023-01904-1 · Cited by 28
Fu, L., Shi, J., Liu, A., Zhou, L., Jiang, M., Fu, H., Xu, K., Li, D., Deng, A., Zhang, Q., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30481 · Cited by 24
Self-citationEffector Caspases and Leukemia
Lu, Y., & Chen, G. (2011) · International Journal of Cell Biology · doi:10.1155/2011/738301 · Cited by 31
“In fact, a previously unknown spliced variant transcript of AML1-ETO (AML1-ETO9a) in AML patients encoding a C-terminally truncated AML1-ETO protein, which could induce rapid development of leukemia in murine retroviral transductiontransplantation model, has been identified in a number of AML patients [70].”
BackgroundDeKelver, R. C., Lewin, B., Lam, K., Komeno, Y., Yan, M., Rundle, C. W., Lo, M., & Zhang, D. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003765 · Cited by 32
“Fetal liver cell isolation, transduction, transplantation and flow cytometry These assays were performed as previously described [10].”
InfluentialSelf-citationDevelopmental-stage-dependent transcriptional response to leukaemic oncogene expression
Regha, K., Assi, S. A., Tsoulaki, O., Gilmour, J., Lacaud, G., & Bonifer, C. (2015) · Nature Communications · doi:10.1038/ncomms8203 · Cited by 27
“Induction at day 0 of the expression of RUNX1-ETO9a, a splice variant of RUNX1-ETO which gives rise to a truncated protein that is capable of causing leukaemia in mice on its own 20 resulted similarly in a defect in generation of CD41+ cells (Supplementary Figures 2a and 2b).”
Lu, Y., Peng, Z.-G., Yuan, T.-T., Yin, Q.-Q., Li, X., & Chen, G.-Q. (2007) · Leukemia · doi:10.1038/sj.leu.2405020 · Cited by 28
Kawashima, N., Akashi, A., Nagata, Y., Kihara, R., Ishikawa, Y., Asou, N., Ohtake, S., Miyawaki, S., Sakura, T., Ozawa, Y., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3492-5 · Cited by 29
Genomics of Acute Myeloid Leukemia
Graubert, T. A., & Mardis, E. R. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823c5652 · Cited by 25
Thiel, V. N., Giaimo, B. D., Schwarz, P., Soller, K., Vas, V., Bartkuhn, M., Blätte, T. J., Döhner, K., Bullinger, L., Borggrefe, T., et al. (2017) · Leukemia · doi:10.1038/leu.2017.105 · Cited by 26
Negative effects of GM-CSF signaling in a murine model of t(8;21)–induced leukemia
Matsuura, S., Yan, M., Lo, M., Ahn, E.-Y., Weng, S., Dangoor, D., Matin, M., Higashi, T., Feng, G., & Zhang, D. (2012) · Blood · doi:10.1182/blood-2011-04-350694 · Cited by 29
Self-citationLiu, N., Song, J., Xie, Y., Wang, X.-L., Rong, B., Man, N., Zhang, M.-M., Zhang, Q., Gao, F.-F., Du, M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809327116 · Cited by 25
“Notably, gene expression analysis of flow cytometry-purified leukemic cells of two mouse models, namely the AML1-ETO9a– and Tet2;AML1ETO–driven leukemic mouse models (69, 70), suggested that E22 could be suppressed in their leukemic cells in comparison with the related nonleukemic cells (SI Appendix, Fig.”
BackgroundSelf-citationMurine Models of Acute Myeloid Leukemia
Kurtz, K. J., Conneely, S. E., O'Keefe, M. B., Wohlan, K., & Rau, R. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.854973 · Cited by 29
Foster, N. A., Paulsson, K. M., Sales, M., Cunningham, J., Groves, M., O’Connor, N., Begum, S., Stubbs, T., McMullan, D. J., Griffiths, M., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08039.x · Cited by 26
“…in break-points within partner genes can also contribute to the heterogeneity of AML, as evident by the increased leukaemogenecity conferred by the spliced isoform of the RUNX1- RUNX1T1 transcript RUNX1- RUNX1T19a, that includes exon 9a, of the RUNX1T1 gene in AML t(8;21) (Yan et al, 2006).”
BackgroundDifferential involvement of E2A-corepressor interactions in distinct leukemogenic pathways
Gow, C., Guo, C. H., Wang, D., Hu, Q., & Zhang, J. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt855 · Cited by 24
“TAFH and NHR2 are the only ETO domains required for AML1-ETO to induce leukemogenesis in a mouse model (31,32).”
BackgroundSteinauer, N., Guo, C. H., Huang, C., Wong, M., Tu, Y., Freter, C. E., & Zhang, J. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028514 · Cited by 28
Shah, V., Giotopoulos, G., Osaki, H., Meyerhöfer, M., Meduri, E., Gallego-Crespo, A., Behrendt, M. A., Saura-Pañella, M., Tarkar, A., Schubert, B., et al. (2024) · Blood · doi:10.1182/blood.2022019306 · Cited by 27
“To validate the effects of BETi in RUNX1-RUNX1T1-rearranged AML in-vivo, we used an Aml1-Eto9a-driven murine AML model 27 .”
RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia
van der Kouwe, E., & Staber, P. B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020350 · Cited by 29
“Respectively lacking the NHR3-4 and the NHR4 domains at the protein level, RUNX1-ETO9a displays a lower capacity to inhibit native RUNX1 [85] but its leukemogenic potential is stronger compared to the unspliced form in mice [86].”
BackgroundNeldeborg, S., Soerensen, J. F., Møller, C. T., Bill, M., Gao, Z., Bak, R. O., Holm, K., Sørensen, B. S., Nyegaard, M., Luo, Y., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01950-9 · Cited by 22
Mouse models for core binding factor leukemia
Chin, D. W. L., Watanabe‐Okochi, N., Wang, C. Q., Tergaonkar, V., & Osato, M. (2015) · Leukemia · doi:10.1038/leu.2015.181 · Cited by 23
Thomsen, I., Kunowska, N., de Souza, R. A., Moody, A.-M., Crawford, G., Wang, Y.-F., Khadayate, S. P., Whilding, C., Strid, J., Karimi, M. M., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001367 · Cited by 22
“These include the RUNX1-ETO fusion, which is the most common cytogenetic abnormality in acute myeloid leukemia (9), and the ETV6-RUNX1 fusion, which occurs in 25% of cases of childhood precursor B cell acute lymphoblastic leukemia (10, 11).”
Self-citationAttenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential
DeKelver, R. C., Yan, M., Ahn, E.-Y. E., Shia, W.-J., Speck, N. A., & Zhang, D. (2013) · Blood · doi:10.1182/blood-2012-11-465641 · Cited by 22
“If AML1-ETO is C-terminally truncated through mutation or alternative splicing, it rapidly induces leukemia.(7,8) AML1-ETO C-terminus interacts with several factors, including nuclear receptor corepressors N-CoR/SMRT(9) and the large nuclear protein SON.”
Self-citationCore Binding Factor Leukemia: Chromatin Remodeling Moves Towards Oncogenic Transcription
Beghini, A. (2019) · Cancers · doi:10.3390/cancers11121973 · Cited by 25
Tijchon, E. J. H., Yi, G., Mandoli, A., Smits, J. G. A., Ferrari, F., Heuts, B. M. H., Wijnen, F., Kim, B., Janssen‐Megens, E. M., Schuringa, J. J., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226435 · Cited by 23
Hyde, R. K., & Liu, P. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22596 · Cited by 23
“2C) [Yan et al., 2006] results in accelerated leukemogenesis.”
BackgroundStructure of the AML1-ETO NHR3–PKA(RIIα) Complex and Its Contribution to AML1-ETO Activity
Corpora, T., Roudaia, L., Oo, Z. M., Chen, W., Manuylova, E., Cai, X., Chen, M. J., Cierpicki, T., Speck, N. A., & Bushweller, J. H. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.08.007 · Cited by 24
“The AML1ETO V601 mutant (+TEL-PDGFβR) caused AML with a similar latent period as AML1-ETO.”
BackgroundInfluentialChen, G., Liu, A., Xu, Y., Gao, L., Jiang, M., Li, Y., Lv, N., Zhou, L., Wang, L., Yu, L., et al. (2019) · FEBS Journal · doi:10.1111/febs.14751 · Cited by 19
Ommen, H. B., Østergaard, M., Yan, M., Brændstrup, K., Zhang, D., & Hokland, P. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01371.x · Cited by 20
“It has recently been shown that the alternative splicing of the RUNX1-RUNX1T1 fusion transcript (FT), which introduces a new exon of 156 nucleotides between exon 8 and exon 9 (exon 9a) (3), results in a truncated protein, and can induce overt leukemia when retrovirally transduced into mice (9).”
BackgroundSelf-citationAML1/ETO Proteins Control POU4F1/BRN3A Expression and Function in t(8;21) Acute Myeloid Leukemia
Dunne, J., Gascoyne, D. M., Lister, T. A., Brady, H. J. M., Heidenreich, O. T., & Young, B. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3604 · Cited by 19
Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization
Schanda, J., Lee, C.-W., Wohlan, K., Müller-Kuller, U., Kunkel, H., Coco, I. Q.-L., Stein, S., Metz, A., Koch, J., Lausen, J., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.161570 · Cited by 19
miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway
Hu, C., Yu, M., Li, C., Wang, Y., Li, X., Ulrich, B. C., Su, R. J., Dong, L., Weng, H., Huang, H., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.44365 · Cited by 20
“, MLL-AF9 + miR-550-1 mut), MSCVneo-AE9a (AML1-ETO9a fusion gene; a truncated AML1-ETO fusion gene causing rapid AML onset in mice [41]) + MSCV-PIG (as control), MSCVneo-AE9a + MSCVPIG-miR-550-1 (i.”
Self-citationMicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3′UTR
Johnson, D. T., Davis, A. G., Zhou, J., Ball, E. D., & Zhang, D. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00204-7 · Cited by 21
Self-citationAhmed, H., Nimmagadda, S. C., Al-Matary, Y. S., Fiori, M., May, T., Frank, D., Patnana, P. K., Récher, C., Schliemann, C., Mikesch, J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17940 · Cited by 21
“Importantly, our investigation validated Notch signalling as one of the important pathways mediating the interaction of AML and MSCs using different murine and human AML cell lines and murine models of human AML.”
MethodInfluentialLaFiura, K. M., Edwards, H. J., Taub, J. W., Matherly, L. H., Fontana, J. A., Mohamed, A. N., Ravindranath, Y., & Ge, Y. (2008) · Oncogene · doi:10.1038/onc.2008.134 · Cited by 25
“The alternate exon 9a (155 bp) identified in ETO (Wolford and Prochazka, 1998) could also be present in the A1E transcripts (Yan et al., 2006).”
BackgroundCore binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis
Guo, M., Chan, H. M. T., Zhou, Q., An, Ö., Li, Y., Song, Y., Tan, Z. H., Ng, H. E. V., Peramangalam, P. S., Tan, Z. Q., et al. (2023) · Blood · doi:10.1182/blood.2022015830 · Cited by 24
Distinct mechanisms of regulation of the ITGA6 and ITGB4 genes by RUNX1 in myeloid cells
Phillips, J. L., Taberlay, P. C., Woodworth, A. M., Hardy, K., Brettingham‐Moore, K. H., Dickinson, J. L., & Holloway, A. F. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26197 · Cited by 17
“In addition, the variant RUNX1-ETO9a transcript, which is detected in Kasumi-1 cells and in 27 of 37 individuals with t(8;21) AML in a previous study, has been found to act as an activator due to the absence of a C-terminal inhibitory domain (Yan et al., 2004; Yan et al., 2006).”
BackgroundCheng, J., Zhang, W., Zhu, J., Cui, D., Song, K., Qiang, P., Mei, C., Nie, Z., Ding, B.-S., Han, Z., et al. (2020) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13440 · Cited by 22
RUNX1/ETO blocks selectin-mediated adhesion via epigenetic silencing of PSGL-1
Ponnusamy, K., Kohrs, N., Ptasinska, A., Assi, S. A., Herold, T., Hiddemann, W., Lausen, J., Bonifer, C., Henschler, R., & Wichmann, C. W. (2015) · Oncogenesis · doi:10.1038/oncsis.2015.6 · Cited by 20
DeKelver, R. C., Lewin, B., Weng, S., Yan, M., Biggs, J. R., & Zhang, D. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.815351 · Cited by 17
Self-citationSupraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation
Link, K. A., Lin, S., Shrestha, M., Bowman, M., Wunderlich, M., Bloomfield, C. D., Huang, G., & Mulloy, J. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524225113 · Cited by 20
“Murine fetal liver (FL) cells transduced with AE9a and transplanted into recipient mice develop a robust AML (14).”
BackgroundEnforced GFI1 expression impedes human and murine leukemic cell growth
Hönes, J. M., Thivakaran, A., Botezatu, L., Patnana, P. K., Castro, S. V. D. C., Al-Matary, Y. S., Schütte, J., Fischer, K. B. I., Vaßen, L., Görgens, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15866-9 · Cited by 22
HHEX promotes myeloid transformation in cooperation with mutant ASXL1
Takeda, R., Asada, S., Park, S., Yokoyama, A., Becker, H., Kanai, A., Visconte, V., Hershberger, C. E., Hayashi, Y., Yonezawa, T., et al. (2020) · Blood · doi:10.1182/blood.2019004613 · Cited by 22
GFI1 is required for RUNX1/ETO positive acute myeloid leukemia
Marneth, A. E., Botezatu, L., Hönes, J. M., Israël, J. C. L., Schütte, J., Vaßen, L., Lams, R. F., Bergevoet, S. M., Groothuis, L., Mandoli, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.180844 · Cited by 16
“The RUNX1/ETO9a transcript is expressed in most primary t(8;21) AML samples.(4) Forced expression of RUNX1/ETO9a in bone marrow (BM) cells causes a rapid development of leukemia in mice.”
BackgroundInfluentialSelf-citationOancea, C., Rüster, B., Brill, B., Roos, J., Heinßmann, M., Bug, G., Mian, A. A., Guillen, N., Kornblau, S. M., Henschler, R., et al. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.39 · Cited by 16
“com/Genes&Cancer Expression of AAFPs in murine hematopoietic stem and progenitor cells (HSPC) recapitulates many features of the leukemic phenotype such as the differentiation block and increased self renewal [5-9].”
BackgroundStorti, F. (2008) · Cited by 16
Lu, L., Wen, Y., Yao, Y., Chen, F., Wang, G., Wu, F., Wu, J., Narayanan, P., Redell, M. S., Mo, Q., et al. (2018) · Theranostics · doi:10.7150/thno.22800 · Cited by 17
“The primary leukemia cells were obtained from a child diagnosed with AML with t(8;21) who was treated at Texas Children’s Cancer Center and whose parents consented to storage of leukemia cells for future research, in accordance with the IRB-approved protocol H-3342.”
BackgroundMethodInfluentialStoner, S. A., Liu, K. T. H., Andrews, E. T., Liu, M., Arimoto, K., Yan, M., Davis, A. G., Weng, S., Dow, M. T., Su, X., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0282-9 · Cited by 17
Self-citationGuo, C. H., Li, J., Steinauer, N., Wong, M., Wu, B., Dickson, A. M., Kalkum, M., & Zhang, J. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010707 · Cited by 16
Smith, I. M., Mithani, S. K., Liu, C., Chang, S. S., Begum, S., Dhara, M., Westra, W. B., Sidranksy, D., & Califano, J. A. (2009) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archoto.2009.43 · Cited by 15
“In vivo studies on variations of RUNX1T1 showed rapid development of leukemia in a normal mouse subjected to retrovirus with this construct.(36) Initially, we showed overexpression (above that of normal controls) in 11 of 36 tumor tissues (31%).”
BackgroundSugimoto, E., Li, J., Hayashi, Y., Iida, K., Asada, S., Fukushima, T., Tamura, M., Shikata, S., Zhang, W., Yamamoto, K., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05606-3 · Cited by 17
Ruthardt (2009) · International Journal of Oncology · doi:10.3892/ijo_00000281 · Cited by 15
Oo, Z. M., Illendula, A., Grembecka, J. E., Schmidt, C., Zhou, Y., Esain, V., Kwan, W., Frost, I. M., North, T. E., Rajewski, R. A., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1410882 · Cited by 14
“inducing leukemia than full length AML1-ETO [52].”
Anderson, G., Mackay, N. A., Gilroy, K. L., Hay, J., Borland, G., McDonald, A., Bell, M., Hassanudin, S. A., Cameron, E. R., Neil, J. C., et al. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26443 · Cited by 14
“In this study we show that attenuation of senescence activity is also a feature of RUNX1-ETO9a, a splice variant of RUNX1-ETO with markedly increased leukemogenicity in mouse models.(26) The paradoxical strong induction of SLGA by RUNX1-ETO appears to be counterbalanced by a prolific SASP response and an ability to pr…”
BackgroundMizushima, Y., Taki, T., Shimada, A., Yui, Y., Hiraumi, Y., Matsubara, H., Watanabe, M., Watanabe, K.-I., Kamitsuji, Y., Hayashi, Y., et al. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0585-x · Cited by 14
Mixed-phenotype acute leukemia (MPAL) and beyond
Kim, H. (2016) · Blood Research · doi:10.5045/br.2016.51.4.215 · Cited by 13
“In the present issue of Blood Research, Pomerantz et al. [9] suggested that a significantly worse disease-free survival and overall survival (OS) noted when comparing MPAL patients to other acute leukemias and better OS in patients treated with ALL-type chemotherapy compared Blood Res 2016;51:215-6. bloodresearch.or.k…”
ResultInfluentialDipeptidylpeptidase 4 promotes survival and stemness of acute myeloid leukemia stem cells
Wang, C., Nistala, R., Cao, M., Pan, Y., Behrens, M., Doll, D. C., Hammer, R., Nistala, P., Chang, H., Yeh, E. T. H., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112105 · Cited by 14
“5,23 Together, our data indicate that DPP4 plays an essential role in the development of AML.”
BackgroundChen, H., Wang, D., Yao, Y., Xiao, Y., Zhao, Z., Zhang, Z., Liu, S., Wang, X., Yang, S., Huang, P., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202411439 · Cited by 12
Kamezaki, K., Luchsinger, L. L., & Snoeck, H. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.11.008 · Cited by 13
“Similar to the MLL-AF9 model, deletion of Flt3 did not affect latency and mortality in leukemia induced by AML-ETO9a, a splice variant of AML1-ETO that induces AML with a very immature lin−kitloFlt3−phenotype in mice[27] (Figure 1a).”
ResultMannari, D., Gascoyne, D. M., Dunne, J., Chaplin, T., & Young, B. D. (2010) · Leukemia · doi:10.1038/leu.2009.288 · Cited by 12
Migas, A. A., Mishkova, V., Ramanouskaya, T. V., Ilyushonak, I. M., Aleinikova, O., & Grinev, V. V. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.06.002 · Cited by 18
“As it was mentioned above many authors assume that RUNX1T1 gene is not expressed in the t(8;21)(q22;q22) positive AML cells [5–7].”
BackgroundProleukemic RUNX1 and CBFβ Mutations in the Pathogenesis of Acute Leukemia
Engel, M. E., & Hiebert, S. W. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-69259-3_8 · Cited by 14
Phosphatase PRL2 promotes AML1-ETO-induced acute myeloid leukemia
Kobayashi, M., Chen, S., Bai, Y., Yao, C., Gao, R., Sun, X.-J., Mu, C., Twiggs, T. A., Yu, Z.-H., Boswell, H. S., et al. (2017) · Leukemia · doi:10.1038/leu.2017.67 · Cited by 15
“13-14 However, a truncated form of the AML1-ETO fusion protein, AML1-ETO9a, is sufficient to cause leukemia in mice.(15) To determine the role of PRL2 in AML1-ETO-induced leukemia in vivo, we introduced AML1-ETO9a (AE9a) into Lin cells isolated from WT and Prl2 null mice using a retrovirus carrying cDNA that encodes t…”
Molecular bases of myelodysplastic syndromes: Lessons from animal models
Komeno, Y., Kitaura, J., & Kitamura, T. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21739 · Cited by 14
“Another example of gene mutation is thought to induce leukemia by itself: a novel truncated isoform of AML1/ETO, AML1/ETO9a, was detected in samples from t(8;21) positive AML (Yan et al., 2006).”
BackgroundZhou, G., Li, G., Chen, S., & Zhu, C. H. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2007.00684.x · Cited by 13
Xu, M., Li, D., Lu, Y., & Chen, G. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.04.018 · Cited by 12
Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion
Chen-Wichmann, L., Shvartsman, M., Preiss, C., Hockings, C., Windisch, R., Monte, E. R., Leubolt, G., Spiekermann, K., Lausen, J., Brendel, C., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0441-7 · Cited by 14
Defective ribosome assembly impairs leukemia progression in a murine model of acute myeloid leukemia
Sjövall, D., Ghosh, S., Fernández‐Fuentes, N., Velasco-Hernández, T., Hogmalm, A., Menéndez, P. R., Hansson, J., Guibentif, C., & Jaako, P. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114864 · Cited by 13
Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond
Chen, S., & Zhou, G. (2012) · IUBMB Life · doi:10.1002/iub.1055 · Cited by 11
“somal translocation which generates two fusion transcripts, the AML1-ETO (AE) (54) and AML1-ETO9a (AE9a) lacking the NHR3-4 domains at C-terminal of ETO moiety (55, 56).”
BackgroundMa, L., Zhang, K., Zhang, Z., Wang, C., Ma, M., Liu, Y., Zhao, Y., Gong, Z., Liu, N., Wei, M., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adt9100 · Cited by 9
Song, M.-J., Kim, H., Park, C., Kim, S.-K., Ki, C., Kim, J., & Kim, S. (2012) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e3182319ebe · Cited by 9
“The remaining 1 patient had AML with anMLL rearrangement/t (11;17) (q23;q25)(patient 43), expected to give rise to MLL/ SEPT9.”
BackgroundInfluentialGupta, S., Dovey, O. M., Domingues, A. F., Cyran, O. W., Cash, C. M., Giotopoulos, G., Rak, J. M., Cooper, J. L., Gozdecka, M., Dijkhuis, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn4886 · Cited by 15
Metadata
- Authors
- Yan, M., Kanbe, E., Peterson, L. F., Boyapati, A., Miao, Y., Wang, Y., Chen, I.-M., Chen, Z., Rowley, J. D., Willman, C. L., & Zhang, D.-E.
- Affiliations
- Scripps Research Institute (US)
- University of New Mexico (US)
- Soochow University (CN)
- University of Chicago (US)
- Corresponding author
- Zhang, Dong-Er
- Venue
- Nature Medicine
- Published
- 2006-07-30
- Volume
- 12
- Issue
- 8
- Pages
- 945-949
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2038583094
- Cited by
- 279
- References
- 30
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 14 · 2023: 17 · 2022: 6 · 2021: 9 · 2020: 11 · 2019: 16 · 2018: 15 · 2017: 19 · 2016: 16 · 2015: 18 · 2014: 13 · 2013: 18 · 2012: 16
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (F32HL079900)
- National Cancer Institute (CA 104509, R01CA096735, CA096735, R01CA104509)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Keywords
- AML1-ETO fusion protein, alternative splicing, RUNX1, RUNX1T1, acute myeloid leukemia, leukemogenesis, myeloid differentiation
- MeSH terms
- RUNX1 Translocation Partner 1 Protein, Amino Acid Sequence, Animals, Cell Line, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 8, Disease Models, Animal, Exons, Humans, Mice, Inbred C57BL, Mice, Inbred Strains, Mice, Transgenic, Molecular Sequence Data, Neoplasm Transplantation, Retroviridae, Translocation, Genetic, Leukemia, Myeloid, Acute, Oncogene Proteins, Fusion, Alternative Splicing, Protein Structure, Tertiary, Jurkat Cells, Protein Isoforms, Core Binding Factor Alpha 2 Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.